Search results
Therapeutic target identified to neutralize toxic forms of Parkinson's-associated protein
Medical Xpress· 3 days agoAlpha-synuclein aggregation is a hallmark of Parkinson's disease and other synucleinopathies. It is a dynamic process in which the protein</ ...
Parkinson’s Disease: What to know
Dayton Daily News· 5 days agoFor a portion of the population, fidgeting and tremors are out of their control, and are hallmarks of a movement disorder called Parkinson’s disease. The...
Research team identifies four new genetic risk factors for multiple system atrophy
Medical Xpress· 1 day agoIn a study published in Neuron, researchers have identified four new genetic risk factors for...
California Assemblymember Laura Friedman Announces Bill to Ban Lethal Agricultural Spray, Paraquat,...
Sierra Sun Times· 10 hours agoThe children are present, but the odiferous, toxic fumes of paraquat wafting from the fields next...
What is dementia? Types, symptoms, causes and treatment
The Telegraph via Yahoo News· 4 days agoBy the year 2040, there will be 1.7 million people in the UK living with dementia, according to the...
Quanterix Corporation (NASDAQ:QTRX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 hours agoQuanterix Corporation (NASDAQ:QTRX) Q1 2024 Earnings Call Transcript May 8, 2024 Quanterix...
A little-understood sleep disorder affects millions and has clear links to dementia – 4 questions...
The Conversation via Yahoo News· 4 days agoIn both situations, REM sleep behavior disorder may be associated with synucleinopathies, a group of...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders - Annovis Bio (NYSE:ANVS)
Benzinga· 4 days agoAnnovis Bio, Inc. ANVS ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced that Maria Maccecchini, Founder ...